var data={"title":"Ampicillin and sulbactam: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ampicillin and sulbactam: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5639?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ampicillin-and-sulbactam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ampicillin and sulbactam: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ampicillin-and-sulbactam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ampicillin and sulbactam: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135090\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Unasyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135112\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135094\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Unasyn (ampicillin/sulbactam) is a combination product. <b>Note:</b> Dosage recommendations are expressed as grams of <b>ampicillin/sulbactam</b> combination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections: </b> IM, IV: 1.5 to 3 g every 6 hours (maximum: 12 g ampicillin/sulbactam daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial rhinosinusitis, severe infection requiring hospitalization (off-label use):</b> IV: 1.5 to 3 g every 6 hours for 5 to 7 days (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amnionitis, cholangitis, diverticulitis, endomyometritis (with doxycycline), endophthalmitis, epididymitis/orchitis, liver abscess (with metronidazole), or peritonitis: </b> IV: 3 g every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal/human) (off-label use):</b> IV: 1.5 to 3 g every 6 hours (human bites) or every 6 to 8 hours (animal bites) (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label use): </b> <i>Enterococcus</i> (native or prosthetic valve; beta-lactamase producing strains resistant to penicillin/susceptible to aminoglycoside and vancomycin): IV: 3 g every 6 hours with a concomitant aminoglycoside for 6 weeks (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravascular catheter-associated bloodstream infection, <i>Acinetobacter</i> spp (off-label use) (IDSA 2009): </b> IV: 3 g every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Orbital cellulitis:</b> IV: 3 g every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis (diabetic foot) (Lipsky 2004): </b> IV: 3 g every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease (alternative to preferred therapy): </b> IV: 3 g every 6 hours with doxycycline oral or IV; transition from parenteral to oral therapy can usually be initiated within 24 to 48 hours of clinical improvement for a total treatment duration of 14 days; if tubo-ovarian abscess is present, at least 24 hours of inpatient observation is recommended (CDC [Workowski 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritonitis associated with CAPD:</b> Intraperitoneal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intermittent:</i> 3 g added to one exchange every 12 hours; allow to dwell for at least 6 hours (Blackwell 1990; Li 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous:</i> Loading dose: 1.5 g per liter of dialysate; maintenance dose: 150 mg per liter of dialysate (Li 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired (off-label use): </b>IV: 1.5 to 3 g every 6 hours for &ge;5 days (Geckler 1994; Majcher-Peszynska 2014; Mandell 2007; Rossoff 1995). <b>Note:</b> In ICU patients, use in combination with azithromycin or a fluoroquinolone (Mandell 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, hospital-acquired or ventilator-associated due to <i>Acinetobacter</i></b> <b>(off-label use):</b> IV: 3 g every 6 hours (Zalts 2016); duration of therapy is 7 days (may consider shorter or longer duration depending on rate of clinical improvement) (Kalil 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use): </b> IV: 3 g within 60 minutes prior to surgical incision. Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infections (intestinal or GI tract) (off-label use): </b> IV: 3 g every 6 hours; in combination with gentamicin or tobramycin (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections, pyelonephritis: </b> IV: 3 g every 6 hours for 14 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135104\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ampicillin-and-sulbactam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ampicillin and sulbactam: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Unasyn (ampicillin/sulbactam) is a combination product. <b>Note:</b> Dosage recommendations are expressed as mg of the <b>ampicillin</b> component.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections: </b> Children and Adolescents: IV: 100 to 200 mg <b>ampicillin/</b>kg/day divided every 6 hours (maximum: 8 g ampicillin daily or 12 g ampicillin/sulbactam daily).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epiglottitis:</b> Children and Adolescents: IV: 100 to 200 mg ampicillin/kg/day divided in 4 doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated (off-label):</b> Infants, Children, and Adolescents: IV: 200 mg ampicillin/kg/day divided every 6 hours; <b>Note:</b> Due to high rates of <i>E. coli</i> resistance, not recommended for the treatment of community-acquired intra-abdominal infections (IDSA [Solomkin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label use):</b> Children and Adolescents: IV: 200 to 300 mg ampicillin/kg/day divided every 4 to 6 hours; maximum dose: 2,000 mg ampicillin/dose; may use in combination with gentamicin, vancomycin, and/or rifampin (optional; dependent upon organism) for at least 4 to 6 weeks; some organisms may require longer duration (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravascular catheter-associated bloodstream infection (off-label use) (IDSA 2009):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: IV: 100 to 150 mg ampicillin/kg/day in 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: IV: 100 to 200 mg ampicillin/kg/day in 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild to moderate infections:</b> Children and Adolescents: IV: 100 to 200 mg ampicillin/kg/day divided every 6 hours (maximum: 8 g ampicillin daily or 12 g ampicillin/sulbactam daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritonsillar and retropharyngeal abscess:</b> Children and Adolescents: IV: 200 mg ampicillin/kg/day in 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe infections:</b> Children and Adolescents: IV: 200 mg ampicillin/kg/day divided every 6 hours (maximum: 8 g ampicillin daily or 12 g ampicillin/sulbactam daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use):</b> Children &ge;1 year: IV: 50 mg ampicillin/kg within 60 minutes prior to surgical incision (maximum: 2 g ampicillin or 3 g ampicillin/sulbactam per dose). Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135095\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135096\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">  <b>Note:</b> Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula. Dosage recommendations are expressed as grams of <b>ampicillin/sulbactam</b> combination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 15 to 29 mL/minute/1.73 m<sup>2</sup>: 1.5 to 3 g every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 5 to 14 mL/minute/1.73 m<sup>2</sup>: 1.5 to 3 g every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">End stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): 1.5 to 3 g  every 12 to 24 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug levels in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment (Heintz 2009; Trotman 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVH: Initial: 3 g; maintenance: 1.5 to 3 g every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVHD: Initial: 3 g; maintenance: 1.5 to 3 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVHDF: Initial: 3 g; maintenance: 1.5 to 3 g every 6 to 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673183\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There is no dosage adjustment provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135070\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution: 1.5 g: Ampicillin 1 g and sulbactam 0.5 g; 3 g: Ampicillin 2 g and sulbactam 1 g; 15 g: Ampicillin 10 g and sulbactam 5 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unasyn:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">1.5 g: Ampicillin 1 g and sulbactam 0.5 g [contains sodium 115 mg (5 mEq)/1.5 g)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">3 g: Ampicillin 2 g and sulbactam 1 g [contains sodium 115 mg (5 mEq)/1.5 g)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">15 g: Ampicillin 10 g and sulbactam 5 g [bulk package; contains sodium 115 mg (5 mEq)/1.5 g)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135054\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135074\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer around-the-clock to promote less variation in peak and trough serum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer by slow injection over 10 to 15 minutes or as an IV infusion over 15 to 30 minutes. Ampicillin and gentamicin should not be mixed in the same IV tubing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillins (eg, ampicillin, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides <i>in vitro</i>. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent Y-site administration should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IM: Inject deep IM into large muscle mass; a concentration of 375 mg/mL ampicillin/sulbactam (250 mg ampicillin/125 mg sulbactam per mL) is recommended; may be diluted in sterile water or lidocaine 0.5% or lidocaine 2% for IM administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135073\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Bacterial infections:</b> Treatment of susceptible bacterial infections involved with skin and skin structure, intra-abdominal infections, gynecological infections; spectrum is that of ampicillin plus organisms producing beta-lactamases such as <i>S. aureus</i>, <i>H. influenzae</i>, <i>E. coli</i>, <i>Klebsiella</i>, <i>Acinetobacter</i>, <i>Enterobacter</i>, and anaerobes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475192\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute bacterial rhinosinusitis; Bite wounds (animal/human); Endocarditis, treatment (adults); Endocarditis, treatment (pediatric); Intra-abdominal infections; Intravascular catheter-associated bloodstream infection; Pneumonia, community acquired; Pneumonia, hospital acquired or ventilator-associated due to Acinetobacter; Surgical prophylaxis; Surgical site infections; Complicated intra-abdominal infections in pediatric patients (IDSA [Solomkin 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135061\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also see Ampicillin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Local: Pain at injection site (IM; 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Thrombophlebitis (3%), phlebitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (IV; 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distention, abdominal pain, acute generalized exanthematous pustulosis, agranulocytosis, anaphylactic shock, anaphylaxis, anemia, angioedema, basophilia, candidiasis, casts in urine (hyaline), chest pain, chills, cholestasis, cholestatic hepatitis, cholestatic jaundice, C<i>lostridium difficile</i> associated diarrhea, constriction of the pharynx, convulsions, decreased hematocrit, decreased hemoglobin, decreased neutrophils, decreased red blood cells, decreased serum albumin, decreased serum total protein, dermatitis, dizziness, drowsiness, dyspepsia, dyspnea, dysuria, edema, eosinophilia, epistaxis, erythema, erythema multiforme, erythrocyturia, exfoliative dermatitis, facial swelling, fatigue, flatulence, gastritis, glossitis, hairy tongue, headache, hemolytic anemia, hepatic insufficiency, hepatitis, hyperbilirubinemia, hypersensitivity reaction, immune thrombocytopenia, increased blood urea nitrogen, increased lactate dehydrogenase, increased liver enzymes, increased monocytes, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum creatinine, injection site reaction, interstitial nephritis, jaundice, leukopenia, lymphocytopenia, lymphocytosis (abnormal), malaise, melena, mucous membrane bleeding, nausea, positive direct Coombs test, pruritus, pseudomembranous colitis, sedation, Stevens-Johnson syndrome, stomatitis, substernal pain, thrombocythemia, thrombocytopenia, toxic epidermal necrolysis, urinary retention, urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135077\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam, or to other beta-lactam antibacterial drugs (eg, penicillins, cephalosporins), or any component of the formulations; history of cholestatic jaundice or hepatic dysfunction associated with ampicillin/sulbactam</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135058\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or a history of sensitivity to multiple allergens. Patients with a history of penicillin hypersensitivity have experienced severe reactions when treated with cephalosporins. Before initiating therapy, carefully investigate previous penicillin, cephalosporin, or other allergen hypersensitivity. If an allergic reaction occurs, discontinue and institute appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic dysfunction: Hepatitis and cholestatic jaundice have been reported (including fatalities). Toxicity is usually reversible. Monitor hepatic function at regular intervals in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rash: Appearance of a rash should be carefully evaluated to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; rash occurs in 5% to 10% of children and is a generalized dull red, maculopapular rash, generally appearing 3-14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Hepatotoxicity has been reported. Monitor hepatic function at regular intervals in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibacterials are not recommended in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298749\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135063\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8745&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atenolol: Ampicillin may decrease the bioavailability of Atenolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: May decrease the serum concentration of Ampicillin. Management: Chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Ampicillin. Management: Administer oral ampicillin at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135066\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6028245\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Both ampicillin and sulbactam cross the placenta. Maternal use of penicillins has generally not resulted in an increased risk of birth defects. When used during pregnancy, pharmacokinetic changes have been observed with ampicillin alone (refer to the Ampicillin monograph for details). Ampicillin/sulbactam may be considered for prophylactic use prior to cesarean delivery (consult current guidelines).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6028246\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ampicillin and sulbactam are both excreted into breast milk in low concentrations. The manufacturer recommends that caution be used if administering to lactating women. Nondose-related effects could include modification of bowel flora and allergic sensitization of the infant. The maternal dose of sulbactam does not need altered in the postpartum period. Also refer to the Ampicillin monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135079\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135068\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor hematologic, renal, and hepatic function; monitor for signs of anaphylaxis during first dose. In patients with preexisting hepatic impairment, monitor hepatic function at regular intervals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135057\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. The addition of sulbactam, a beta-lactamase inhibitor, to ampicillin extends the spectrum of ampicillin to include some beta-lactamase-producing organisms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135076\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ampicillin:</b> See Ampicillin monograph.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sulbactam:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Distribution: Widely distributed to bile, blister, and tissue fluids; poor penetration into CSF with uninflamed meninges; higher concentrations attained with inflamed meninges; V<sub>d</sub> (Nahata 1999): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to 12 years: ~0.35 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 0.25 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protein binding: 38% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Half-life elimination: Children 1 to 12 years (normal renal function): Mean range: ~0.7 to 0.9 hours (Nahata 1999); Adults (normal renal function): 1 to 1.3 hours; <b>Note:</b> Elimination kinetics of both ampicillin and sulbactam are similarly affected in patients with renal impairment, therefore, the blood concentration ratio is expected to remain constant regardless of renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Excretion: Urine (~75% to 85% as unchanged drug) within 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322990\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ampicillin-Sulbactam Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 (1-0.5) g (1): $4.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 (2-1) g (1): $7.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 (10-5) g (1): $71.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ampicillin-Sulbactam Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 (1-0.5) g (1): $6.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 (2-1) g (1): $10.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 (10-5) g (1): $39.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Unasyn Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 (1-0.5) g (1): $9.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 (2-1) g (1): $17.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 (10-5) g (1): $86.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038527\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aepisul (PH);</li>\n      <li>Ambacillin (TW);</li>\n      <li>Ambacitam (TH);</li>\n      <li>Ampictam (SY);</li>\n      <li>Ampigen SB (AR);</li>\n      <li>Ampimax (PH);</li>\n      <li>Ampisulbin (UA);</li>\n      <li>Ampisulciillin (BG);</li>\n      <li>Ampisulcillin (EE);</li>\n      <li>Amplisul (EC);</li>\n      <li>Amsubac (TH);</li>\n      <li>Ansutam (TW);</li>\n      <li>Auropennz (CL);</li>\n      <li>Baccillin (KR);</li>\n      <li>Bactesyn (ID);</li>\n      <li>Bethacil (IT);</li>\n      <li>Cinam (ID);</li>\n      <li>Easyn (MY);</li>\n      <li>Libractam (PY, UY);</li>\n      <li>Prixin (AR, PY);</li>\n      <li>Rexatam (TH);</li>\n      <li>Rukasyn (KR);</li>\n      <li>Shinasyn (MY);</li>\n      <li>Silgram (PH);</li>\n      <li>Sulam (TH);</li>\n      <li>Sulbaccin (TH);</li>\n      <li>Sulbacin (IN, KR, PH);</li>\n      <li>Sultamicilina (AR);</li>\n      <li>Ubacsin (KR);</li>\n      <li>Ubactam (KR);</li>\n      <li>Ultramox (PH);</li>\n      <li>Unacid (DE);</li>\n      <li>Unacim (FR);</li>\n      <li>Unasyn (AE, AT, BB, BF, BG, BH, BJ, BR, CI, CL, CN, CO, CR, CY, CZ, EC, EE, EG, GN, GT, HK, HN, HU, ID, IL, IQ, IR, IT, JO, KR, KW, LB, LT, LV, LY, MA, ML, MR, MY, NE, NI, OM, PA, PE, PH, PK, PL, QA, RO, SA, SD, SG, SI, SK, SN, SV, SY, TH, TN, UY, VN, YE, ZA);</li>\n      <li>Unazyn (UA);</li>\n      <li>Xilbac (CO, EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blackwell BG, Leggett JE, Johnson CA, et al, &ldquo;Ampicillin and Sulbactam Pharmacokinetics and Pharmacodynamics in Continuous Ambulatory Peritoneal Dialysis (CAPD),&rdquo; <i>Perit Dial Int</i>, 1990, 10(3):221-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/2099158/pubmed\" target=\"_blank\" id=\"2099158\">2099158</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blum RA, Kohli RK, Harrison NJ, et al, &ldquo;Pharmacokinetics of Ampicillin (2.0 Grams) and Sulbactam (1.0 Gram) Coadministered to Subjects With Normal and Abnormal Renal Function and With End-Stage Renal Disease on Hemodialysis,&rdquo; <i>Antimicrob Agents Chemother</i>, 1989, 33(9):1470-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/2817847 /pubmed\" target=\"_blank\" id=\"2817847 \">2817847 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani R, and Nightingale CH, &ldquo;<i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,&rdquo; <i>JAMA</i>, 1982, 247(5):658-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dajani AS, &ldquo;Sulbactam/Ampicillin in Pediatric Infections,&rdquo; <i>Drugs</i>, 1988, 35(Suppl 7):35-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al, &ldquo;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&quot; <i>J Perinatol</i>, 1997, 17(1):42-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al, &ldquo;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&rdquo; <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA, &ldquo;Inactivation of Aminoglycosides by Penicillins,&rdquo; <i>J Antimicrob Chemother</i>, 1982, 8(Suppl A):27-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs PC, Stickel S, Anderson PH, et al, &ldquo;<i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(1):182-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/2014975/pubmed\" target=\"_blank\" id=\"2014975\">2014975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7982254\"></a>Geckler RW. A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract. <i>Clin Ther</i>. 1994;16(4):662-672.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/7982254/pubmed\" target=\"_blank\" id=\"7982254\">7982254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldfarb J, Aronoff SC, Jaff&eacute; A, et al, &ldquo;Sultamicillin in the Treatment of Superficial Skin and Soft Tissue Infections in Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1987, 31(4):663-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/3038003/pubmed\" target=\"_blank\" id=\"3038003\">3038003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halstenson CE, Wong MO, Herman CS, et al, &ldquo;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&rdquo; <i>Antimicrob Agents Chemother</i>, 1992, 36(9):1832-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/1416875/pubmed\" target=\"_blank\" id=\"1416875\">1416875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al, &ldquo;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Itokazu GS and Danziger LH, &ldquo;Ampicillin-Sulbactam and Ticarcillin-Clavulanic Acid: A Comparison of Their <i>In Vitro</i> Activity and Review of Their Clinical Efficacy,&rdquo; <i>Pharmacotherapy</i>, 1991, 11(5):382-414.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/1745624/pubmed\" target=\"_blank\" id=\"1745624\">1745624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27521441\"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society. <i>Clin Infect Dis</i>. 2016;63(5):575-582.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/27521441/pubmed\" target=\"_blank\" id=\"27521441\">27521441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konishi H, Goto M, Nakamoto Y, et al, &ldquo;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&rdquo; <i>Antimicrob Agents Chemother</i>, 1983, 23(5):653-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/6223576/pubmed\" target=\"_blank\" id=\"6223576\">6223576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulhanjian J, Dunphy MG, Hamstra S, et al, &ldquo;Randomized Comparative Study of Ampicillin/Sulbactam vs Ceftriaxone for Treatment of Soft Tissue and Skeletal Infections in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1989, 8(9):605-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/2677956/pubmed\" target=\"_blank\" id=\"2677956\">2677956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau A, Lee M, Flascha S, et al, &ldquo;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,&rdquo; <i>Antimicrob Agents Chemother</i>, 1983, 24(4):533-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/6651279/pubmed\" target=\"_blank\" id=\"6651279\">6651279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li PK, Szeto CC, Piraino B, et al, &quot;Peritoneal Dialysis-Related Infections Recommendations: 2010 Update,&quot; <i>Perit Dial Int</i>, 2010, 30(4):393-423<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/20628102/pubmed\" target=\"_blank\" id=\"20628102\">20628102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23904004\"></a>Majcher-Peszynska J, Loebermann M, Klammt S, et al. CAPNETZ Study Group. Ampicillin/sulbactam in elderly patients with community-acquired pneumonia. <i>Infection</i>. 2014;42(1):79-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/23904004/pubmed\" target=\"_blank\" id=\"23904004\">23904004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al, &ldquo;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2009, 49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyers BR, Wilkinson P, Mendelson MH, et al, &ldquo;Pharmacokinetics of Ampicillin-Sulbactam in Healthy Elderly and Young Volunteers,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(10):2098-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/1759832/pubmed\" target=\"_blank\" id=\"1759832\">1759832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahata MC, Vashi VI, Swanson RN, et al, &quot;Pharmacokinetics of Ampicillin and Sulbactam in Pediatric Patients,&quot; <i>Antimicrob Agents Chemother</i>, 1999, 43(5):1225-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oehler RL, Velez AP, Mizrachi M, et al, &ldquo;Bite-Related and Septic Syndromes Caused by Cats and Dogs,&rdquo; <i>Lancet Inf Dis</i>, 2009, 9(7):439-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/19555903/pubmed\" target=\"_blank\" id=\"19555903\">19555903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rafailidis PI, Ioannidou EN, and Falagas ME, &ldquo;Ampicillin/Sulbactam: Current Status in Severe Bacterial Infections,&rdquo; <i>Drugs</i>, 2007, 67(13):1829-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/17722953/pubmed\" target=\"_blank\" id=\"17722953\">17722953</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rho SP, Jones A, Woo M, et al, &ldquo;Single Dose Pharmacokinetics of Intravenous Ampicillin Plus Sulbactam in Healthy Elderly and Young Subjects,&rdquo; <i>J Antimicrob Chemother</i>, 1989, 24(4):573-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/2613605/pubmed\" target=\"_blank\" id=\"2613605\">2613605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rossoff LJ, Hilton E, Smith C, Isenberg HD, Simme MM. Intravenous ampicillin/sulbactam versus cefuroxime axetil in the treatment of patients hospitalized with community-acquired lower respiratory tract infections. <i>Curr Ther Res</i>. 1995;56(9):852-862.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russoe ME and Atkins-Thor E, &ldquo;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&quot; <i>Clin Nephrol</i>, 1981, 15(4):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/7237864/pubmed\" target=\"_blank\" id=\"7237864\">7237864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20034345\"></a>Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Syriopoulou V, Bitsi M, Theodoridis C, et al, &ldquo;Clinical Efficacy of Sulbactam/Ampicillin in Pediatric Infections Caused by Ampicillin-Resistant or Penicillin-Resistant Organisms,&rdquo; <i>Rev Infect Dis</i>, 1986, 8(Suppl 5):630-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson MIB, Russo ME, Saxon BJ, et al, &ldquo;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&rdquo; <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/6462107/pubmed\" target=\"_blank\" id=\"6462107\">6462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Unasyn (ampicillin sodium and sulbactam sodium) [prescribing information]. New York, NY: Roerig; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viollier AF, Standiford HC, Drusano GL, et al, &ldquo;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin, and Piperacillin, With and Without Gentamicin,&rdquo; <i>J Antimicrob Chemother</i>, 1985, 15(5):597-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/4008387/pubmed\" target=\"_blank\" id=\"4008387\">4008387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald E, Reilly JS, Bluestone CD, et al, &ldquo;Sulbactam/Ampicillin in the Treatment of Acute Epiglottitis in Children,&rdquo; <i>Rev Infect Dis</i>, 1986, 8(Suppl 5):617-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/3026014/pubmed\" target=\"_blank\" id=\"3026014\">3026014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterspiel JN, Feldman S, Van R, et al, &ldquo;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(9):1875-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/1952861/pubmed\" target=\"_blank\" id=\"1952861\">1952861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ, &ldquo;The Penicillins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL and Bergman SA, &ldquo;Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,&rdquo; <i>Gen Dent</i>, 1994, 42(5):398-402, 498-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/7489869/pubmed\" target=\"_blank\" id=\"7489869\">7489869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24263165\"></a>Zalts R, Neuberger A, Hussein K. Treatment of carbapenem-resistant acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam. <i>Am J Ther</i>. 2016;23(1):e78-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information/abstract-text/24263165/pubmed\" target=\"_blank\" id=\"24263165\">24263165</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8745 Version 149.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135090\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135112\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135094\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F135104\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135095\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F135096\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673183\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135070\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135054\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F135074\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135073\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475192\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135061\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135077\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135058\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298749\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F135063\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135066\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6028245\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6028246\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F135079\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F135068\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135057\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F135076\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322990\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038527\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8745|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ampicillin-and-sulbactam-patient-drug-information\" class=\"drug drug_patient\">Ampicillin and sulbactam: Patient drug information</a></li><li><a href=\"topic.htm?path=ampicillin-and-sulbactam-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin and sulbactam: Pediatric drug information</a></li></ul></div></div>","javascript":null}